| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/24/2001 | CN1280855A Medicinal composition containing algal protein polyose extract and extraction of algal protein polyose |
| 01/24/2001 | CN1280840A Chinese-medicinal plaster for treating spontaneous or night sweating and its preparing process |
| 01/24/2001 | CN1280825A Sigma-receptor acting medicine containing protopine-type alkaloid |
| 01/24/2001 | CN1061049C Sulfur-containing phosphonate compounds, pharmaceutical compositions and use thereof |
| 01/24/2001 | CN1061044C Tricyclic 5,6-dihydro-9H-pyrazolo [3,4-C]-1,2,4-triaolo [4,3-alpha] pyridines |
| 01/24/2001 | CN1061041C Piperidine derivatives |
| 01/23/2001 | US6177572 Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use |
| 01/23/2001 | US6177474 Aromatic compound containing ketone and hydroxy groups |
| 01/23/2001 | US6177470 Prostaglandin synthesis |
| 01/23/2001 | US6177458 Alzheimer's disease |
| 01/23/2001 | US6177450 Synergizing combination having an antagonist effect on NKI and NK2 receptors |
| 01/23/2001 | US6177448 Therapy for chemokine sensitivie disease |
| 01/23/2001 | US6177447 Therapy for gaucher's disease |
| 01/23/2001 | US6177436 Administering with viricide; side effect reduction |
| 01/23/2001 | US6177432 Farnesyltransferase inhibiting quinazolinones |
| 01/23/2001 | US6177429 Dihydropyrazine derivatives as NPY antagonists |
| 01/23/2001 | US6177428 Treatment of sexual dysfunction; stimulation of endogenous nitrogen monoxide synthesis |
| 01/23/2001 | US6177426 Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors |
| 01/23/2001 | US6177425 Stereospecific enantiomer having antiinflammatory and neutrophil elastase inhibiting activity; for treatment of chronic bronchitis in humans or animals |
| 01/23/2001 | US6177420 Fertility control agents; side effect reduction |
| 01/23/2001 | US6177402 Promoting survival of mammalian sensory neurons by contacting with leukemia inhibitory factor (lif) |
| 01/23/2001 | US6177246 Contacting a tissue or cell with an oligonucleotide of defined nucleotide sequence which hybridizes to nucleic acid encoding abnormally expressed beta-amyloid precursor protein; prophylaxis and treatment of alzheimer's disease |
| 01/23/2001 | US6177245 Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms |
| 01/23/2001 | US6177060 Nmr or x-ray lymphography images |
| 01/23/2001 | CA2197272C Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6- chloro-1,3-dihydro-2h-indol-2-one |
| 01/23/2001 | CA2196885C Carboxamide compounds (changed to n-(2-(pyrrolidinyl-1)-1-phenylethyl) acetamides as kappa receptor antagonists) |
| 01/23/2001 | CA2022451C Anti-psychotic piperidynl benzimidazole compounds |
| 01/23/2001 | CA2021340C Cyclic vinylogous n-hydroxy-n-methylureas useful as 5-lipoxygenase inhibitors |
| 01/22/2001 | CA2746824A1 Neurotherapeutic composition and method |
| 01/20/2001 | WO2001005376A1 New pharmaceutical formulation |
| 01/20/2001 | CA2328102A1 New pharmaceutical formulation |
| 01/18/2001 | WO2001004354A2 Use of ras inhibitors of inhibiting muscle atrophy |
| 01/18/2001 | WO2001004344A2 Induction of a th1-like response in vitro |
| 01/18/2001 | WO2001004341A1 Method for producing oligopolysaccharides |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004282A2 Replication-competent anti-cancer vectors |
| 01/18/2001 | WO2001004264A2 Atherosclerosis-associated genes |
| 01/18/2001 | WO2001004146A2 Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
| 01/18/2001 | WO2001004133A1 Human eag2 |
| 01/18/2001 | WO2001004125A1 Staurosporin derivatives |
| 01/18/2001 | WO2001004118A2 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
| 01/18/2001 | WO2001004111A1 Anilinoquinazolines as protein tyrosine kinase inhibitors |
| 01/18/2001 | WO2001004102A1 Quinazoline derivatives |
| 01/18/2001 | WO2001004099A1 Benzoylpyridazines |
| 01/18/2001 | WO2001004083A1 Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the cb2 cannabinoid receptor |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003740A1 Serine protease inhibitor |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003717A2 Methods of inducing cell death |
| 01/18/2001 | WO2001003716A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | WO2001003707A1 Heartburn treatment |
| 01/18/2001 | WO2001003705A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | WO2001003704A1 Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis |
| 01/18/2001 | WO2001003692A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2001003684A2 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 01/18/2001 | WO2001003673A1 Dry powder compositions |
| 01/18/2001 | WO2001003657A1 Topically applied idebenone-containing agent with protective and regenerative effect |
| 01/18/2001 | WO2000066099A3 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| 01/18/2001 | WO2000062744A3 Skin care compositions containing combination of skin care actives |
| 01/18/2001 | WO2000056864A3 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/18/2001 | WO2000034245A3 Crystalline form of benzoquinoline-3-one derivatve as inhibitor of 5-alpha reductase |
| 01/18/2001 | WO2000031092A3 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 01/18/2001 | WO2000023565B1 Novel neuropilin/growth factor binding and uses thereof |
| 01/18/2001 | WO2000002911A3 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/18/2001 | WO1999064049A9 Novel antibacterial agents |
| 01/18/2001 | WO1999050403A3 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses |
| 01/18/2001 | DE19933173A1 Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶ |
| 01/18/2001 | DE19933089A1 Mittel zur Gewerbsregeneration Means for commercial regeneration |
| 01/18/2001 | DE19932197A1 Topisch anzuwendendes Mittel mit schützender und regenerativer Wirkung Topically applied agents with protective and regenerative effect |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2379035A1 Staurosporin derivatives |
| 01/18/2001 | CA2379010A1 Methods of inducing cell death |
| 01/18/2001 | CA2378985A1 Atherosclerosis-associated genes |
| 01/18/2001 | CA2378982A1 Methods of inhibiting muscle atrophy |
| 01/18/2001 | CA2378610A1 Human eag2 |
| 01/18/2001 | CA2378600A1 Amino ceramide-like compounds and therapeutic methods of use |
| 01/18/2001 | CA2378595A1 Benzoylpyridazines |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378562A1 Method for producing oligopolysaccharides |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378402A1 Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
| 01/18/2001 | CA2378291A1 Quinazoline derivatives |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2378097A1 Induction of a th1-like response in vitro |
| 01/18/2001 | CA2378018A1 Heartburn treatment |
| 01/18/2001 | CA2377999A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | CA2377918A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | CA2375640A1 Dry powder compositions |
| 01/17/2001 | EP1069132A1 Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1069114A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/17/2001 | EP1068867A2 Pharmaceutical tablet comprising an NSAID and misoprostol |
| 01/17/2001 | EP1068522A1 Antigen |
| 01/17/2001 | EP1068338A2 Enhanced prodrug activation |
| 01/17/2001 | EP1068336A2 Membranemetalloprotease nepii |
| 01/17/2001 | EP1068315A2 Therapeutic agent for ngf |
| 01/17/2001 | EP1068221A2 Template associated npy y2-receptor agonists |